Table 1 Patient characteristics at baseline
Characteristic | n (%) |
|---|---|
Patients receiving treatment | 60 (100) |
Median age (range), years | 54 (31–81) |
ECOG PS | Â |
 0 | 31 (52) |
 1 | 29 (48) |
Disease stage | Â |
 Locally recurrent | 2 (3) |
 Metastatic | 58 (97) |
Histologic type | Â |
 Ductal | 51 (85) |
 Ductal and lobular | 1 (2) |
 Ductal and other | 1 (2) |
 Lobular | 3 (5) |
 Other | 4 (7) |
Receptor status | Â |
 Estrogen receptor-positive | 33 (55) |
 Progesterone receptor-positive | 22 (37) |
 HER2-positive* | 60 (100) |
Prior systemic therapy | 44 (73) |
 Anthracycline + trastuzumab or lapatinib | 26 (43) |
 Anthracycline only | 11 (18) |
 Trastuzumab only | 4 (7) |
 Lapatinib only | 2 (3) |
 Other | 1 (2) |
 No prior systemic therapy | 16 (27) |
Prior chemotherapy in metastatic setting | Â |
 Yes | 25 (42) |
 No | 35 (58) |
Location of disease | Â |
 Regional or distant lymph node | 35 (58) |
 Lung | 27 (45) |
 Bone | 25 (42) |
 Liver | 24 (40) |